INTRODUCTION
Skin rejuvenation treatments, including chemical peels and biostimulatory therapies, improve signs of aging; however, they have limitations, including invasiveness, efficacy, safety, and extensive downtime.1
Chemical peels are well-known for skin rejuvenation benefits, including improvement in skin texture, fine lines, and wrinkles. Chemical peels traditionally utilize glycolic, lactic, and salicylic acids to target the outermost skin layers to improve texture and tone. However, they do not directly address collagen and elastin regeneration. Additionally, the lack of innovation in acid types utilized prevents treatment optimization. There may be a broader scope of bioactive acids to enhance efficacy.2,3 Biostimulatory treatments induce dermal remodeling through a targeted approach. However, these treatments are invasive and have limitations, including efficacy, safety, and recovery time.4
With the advancement of modern technology, individuals can achieve the skin rejuvenation benefits of traditional invasive and non-invasive therapies with limited patient downtime.5 Plant-derived bioactive compounds are unique and target multiple aging pathways, by providing antioxidant and anti-inflammatory benefits, while being well tolerated with a high safety profile.6-7
An Antioxidant Biostimulating Treatment (ABT) was formulated with a multi-acid delivery system, where a chemoexfoliation base, including typical alpha- and beta-hydroxy acids, induces epidermal exfoliation to optimally deliver a unique blend of biostimulating phytocompound acids. These biostimulating phytocompound antioxidant acids, including betulinic, oleanolic, asiatic, ursolic, and madecassic acids, upregulate collagen I and elastin for skin rejuvenation.8 In a previous 12-week open-label clinical study, the ABT improved fine lines, skin laxity and texture, pores, radiance, and clarity in individuals with Fitzpatrick Skin Types (FST) I to V.8
This case study expands the previous investigation to include FST VI. We hypothesize the ABT will improve clinical outcomes in skin of color patients after a series of three progressive sessions, every 4 weeks, without adverse events.
Chemical peels are well-known for skin rejuvenation benefits, including improvement in skin texture, fine lines, and wrinkles. Chemical peels traditionally utilize glycolic, lactic, and salicylic acids to target the outermost skin layers to improve texture and tone. However, they do not directly address collagen and elastin regeneration. Additionally, the lack of innovation in acid types utilized prevents treatment optimization. There may be a broader scope of bioactive acids to enhance efficacy.2,3 Biostimulatory treatments induce dermal remodeling through a targeted approach. However, these treatments are invasive and have limitations, including efficacy, safety, and recovery time.4
With the advancement of modern technology, individuals can achieve the skin rejuvenation benefits of traditional invasive and non-invasive therapies with limited patient downtime.5 Plant-derived bioactive compounds are unique and target multiple aging pathways, by providing antioxidant and anti-inflammatory benefits, while being well tolerated with a high safety profile.6-7
An Antioxidant Biostimulating Treatment (ABT) was formulated with a multi-acid delivery system, where a chemoexfoliation base, including typical alpha- and beta-hydroxy acids, induces epidermal exfoliation to optimally deliver a unique blend of biostimulating phytocompound acids. These biostimulating phytocompound antioxidant acids, including betulinic, oleanolic, asiatic, ursolic, and madecassic acids, upregulate collagen I and elastin for skin rejuvenation.8 In a previous 12-week open-label clinical study, the ABT improved fine lines, skin laxity and texture, pores, radiance, and clarity in individuals with Fitzpatrick Skin Types (FST) I to V.8
This case study expands the previous investigation to include FST VI. We hypothesize the ABT will improve clinical outcomes in skin of color patients after a series of three progressive sessions, every 4 weeks, without adverse events.
PATIENTS AND METHODS
A single-center, open-label, IRB-approved, 12-week case study assessed the ABT efficacy and tolerability on 11 healthy female subjects aged 45 to 65, with FST V–VI and mild to moderate global facial radiance, skin smoothness, and overall appearance, based on a 10-point modified Griffiths scale.9
